Showing 1821-1830 of 2038 results for "".
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Diseasehttps://modernod.com/news/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-school-to-license-third-program-for-inherited-retinal-disease/2480431/Opus Genetics, a gene therapy company developing treatments for orphan inherited retinal diseases, announced an agreement to license its third preclinical program to address mutations in the NMNAT1 gene, which cause a specific form of Leber congenital amaurosis (LCA), from Massa
- Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presbyopia/2480400/Eyenovia announced that the first patient has been enrolled in the company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in presbyopia, known as VISION-2. “Following the co
- Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDAhttps://modernod.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device com
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- FYidoctors Makes Expansion into US Markethttps://modernod.com/news/fyidoctors-makes-expansion-into-us-market/2480296/Canadian eye care provider FYidoctors announced that it has expanded its geographic operations into the US marketplace with the addition of six leading eye care clinics throughout the state of California. The foray marks a major company milestone as the first time FYidoctors has ad
- Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-industry-leaders-tracy-valorie-and-dwight-moxie-to-board-of-directors/2479470/Visus Therapeutics announced the appointments of Tracy Valorie, former Senior Vice President and General Manager, US Ophthalmology Rx and Surgical at Bausch + Lomb; and Dwight Moxie, Senior Vice President, General Counsel and Corporate Secretary at Revance Therapeutics to its Board of Directors.<
- Santen and Sydnexis Execute an Exclusive Licensing Agreement for SYD-101, an Investigational Treatment for Progressive Childhood Myopiahttps://modernod.com/news/santen-and-sydnexis-execute-an-exclusive-licensing-agreement-for-syd-101-a-novel-investigational-treatment-for-progressive-childhood-myopia/2479443/Santen and Sydnexis have signed an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation for childhood myopia, for Europe, the Middle East, and Africa (EMEA). SYD-101 is currently undergoing a large multicenter phase 3 clinical trial, the S
- Scientists Discover Gene Therapy Provides Neuroprotection to Prevent Glaucoma Vision Losshttps://modernod.com/news/scientists-discover-gene-therapy-provides-neuroprotection-to-prevent-glaucoma-vision-loss/2479407/A form of gene therapy protects optic nerve cells and preserves vision in mouse models of glaucoma, according to research supported by NIH’s National Eye Institute. The findings suggest a way forward for developing neuroprotective therapies for glaucoma, a leading cause of visual impairment and b
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati